Drug therapy for macular oedema treatment approved

Article

Ozurdex, the first drug therapy for the treatment of macular oedema, following branch retinal vein occlusion or central retinal vein occlusion, has been approved by the FDA.

Ozurdex, the first drug therapy for the treatment of macular oedema, following branch retinal vein occlusion or central retinal vein occlusion, has been approved by the FDA.

It comprises a biodegradable, injectable steroid implant with extended drug release. It is administered via intravitreal injection and delivers extended release of a highly potent corticosteroid using the company's proprietary solid polymer delivery system, Novadur.

"Ozurdex represents the first injectable, sustained release, potent steroid implant that provides prolonged efficacy and a favourable safety profile. In clinical studies, 20-30% of patients suffering from this retinal condition experienced a 3-line improvement in best-corrected visual acuity with an onset of effect within the first two months following therapy," said Scott Whitcup, Allergan's executive vice president, R&D and chief scientific officer.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
© 2025 MJH Life Sciences

All rights reserved.